MATWIN Programme 2015

Support for the Proof of Concept

Project Application Form

For internal use only:		
Cancéropôle partner:	*Date of receipt:*	*File number:*

MATWIN *is a nationwide programme that identifies and supports the maturation of oncology research projects up to the preclinical Proof of Concept. The present form presents your project from an industrial point of view. The assessment is a major step of the process. The project will be assessed according to five criteria: (i) innovation components & value, (ii) translational potential, (iii) commercial potential & competitive landscape, (iv) technology transfer setup & value creation, (v) project feasibility & project management. For assistance do not hesitate to ask technology your transfer office and/or institution partner (Cancéropôle, research institution…).*

Before filling a MATWIN form (Eurobiomed "Petit guide des questions à poser avant de se lancer dans un projet collaboratif innovant"):

- *A clear and precise project → you must be able to describe your project in two sentences.*
- *An original and innovative project → in what your project is original in relation to the existent; what differentiates your project from the national and international competition; what results and knowledge must be protected (PI) or acquired (license)?*
- *A vision of the market with concrete outcomes → the size of the potential worldwide market resulting from the project; what is the aimed segment thanks to your technology, product or service; what are the benefits for users (patient, prescriber, payer, medical insurance); the essential tools to address this market share (positioning)?*
- *A consistent development plan → a provisional budget for the duration of the project; the necessary chaining tasks for the realization of the project plan (who makes what, milestones, go/no go); the way of creating value on the project (exclusive license, internal development, product's time-to-market)?*
- *An appropriate organization for shared results → a skill-based network of professional partners; each project's partner must be able to benefit from results and value-creation; the management to assure a good quality.*

Research Project

Title	
Acronym	
Key words	

Project Coordinator

Title; Name			
Position			
Name office			
Address			
E-mail		**Phone / Mobile**	

Technology Transfer Office – Patent Office

Name office			
Contact name			
Address			
E-mail		**Phone / Mobile**	

TABLE OF CONTENTS

CONTACT DETAILS

The application form must be returned both to:
☞ The MATWIN Platform by e-mail a pdf format
☞ The Cancéropôle Partner by e-mail a pdf format **&** by mail the original copy

MATWIN - Cancéropôle IDF – Cécile FAURIE
Institut Bergonié, 229 cours de l'Argonne 33076 Bordeaux cedex
💻 cecile.faurie@matwin.org;
☎ 06 84 01 61 70

Cancéropôle CLARA – Ophélie PHILIPOT
Bâtiment Domilyon, 321 avenue Jean Jaurès 69007 Lyon
💻 ophilipot@canceropole-clara.com;
☎: 04 37 90 17 25

Cancéropôle GE – Rachel GROUBET
Hôpital de Hautepierre, 1av. Molière 67098 Strasbourg
💻 rachel.groubet@canceropole-ge.org;
☎ 03 88 12 84 19

Cancéropôle GO – Jean-Luc CAILLOT
Maison de la Recherche en Santé, 63 quai Magellan 44000 Nantes
💻 jeanluc.caillot@chu-nantes.fr;
☎ 02 53 48 28 75

Cancéropôle GSO – Karine MARENDZIAK
Hôpital La Grave, Place Lange TSA 60033 31059 Toulouse cedex 9
💻 karine.marendziak@canceropole-gso.org;
☎ 06 82 76 75 07

Cancéropôle NO – Véronique PANCRE
6 rue du Pr Laguesse, CS 50027 59045 Lille cedex
💻 veronique.pancre@canceropole-nordouest.org;
☎ 03 20 74 35 83

Cancéropôle PACA – Clara DUCORD
Faculté de Médecine – Timone, 27 bld Jean Moulin 13005 Marseille
💻 clara.ducord@univ-amu.fr;
☎ 04 91 32 47 02

☞ : www.matwin.org

PROJECT IDENTITY CARD

Project classification status & current concepts

Organ Sites		Immunology	
Bone Cancer		Cancer immunotherapy, preclinical and clinical	
Brain Cancer		Clinical immunology, biological therapy	
Breast Cancer		Tumour immunobiology	
Endocrine/Neuroendocrine Cancer		**Medical device**	
Gastrointestinal/Oesophageal Cancer		Analytical test	
Genitourinary / Gynaecologic Cancer		Prototype (α, β, pre-industrial)	
Haematological Malignancies		Test development	
Head and Neck Cancer		Validation	
Lung/Bronchus Cancer		**Molecular and cellular biology**	
Lymphoid Malignancies		Cancer systems biology	
Melanoma		Cell cycle	
Metastasis		Cell death	
Nervous System Cancer		Cell growth signalling pathways	
Paediatric Cancer		Cellular stress responses	
Pancreatic Adenocarcinoma		Chromosome / DNA damage and repair	
Prostate Cancer		Epigenetics	
Sarcomas and Soft Tissue Cancer		Innovative technologies in cancer research	
Skin Cancer		Metabolism and cancer	
Other…		MicroRNAs and other noncoding RNAs	
Biomarkers; Early detection		Molecular genetics	
Diagnostic		Oncogenes and tumours suppressor genes	
Predictive		Oncogene regulation and transcription factors	
Prognostic		**Targets**	
Technology development and/or marker discovery		Target identification	
Technology and/or marker evaluation		Target validation	
Technology and/or marker testing in a clinical setting		**Technological platforms**	
Cancer chemistry		Genomics	
Drug delivery		Imaging	
Drug discovery and design		Metabolomics	
Imaging agents and radio-therapeutics		Proteomics	
Proteomics, metabolomics, biological mass spectrometry		**Therapeutics – small molecules**	
Structural and chemical biology		indirect action, anti-angiogenic, anti-metastatic	
Discovery		targeted action, cellular signal transduction inhibitor	
In vitro studies		resistance modifiers, DNA repair, drug efflux inhibitors	
In vivo studies		miscellaneous antibodies	
Preclinical		Other biological: gene cellular, protein…	
Experimental and molecular therapeutics		**Treatment - therapy**	
Biological therapeutic agents		Localised: discovery, development, clinical application	
Drug discovery		Systemic: discovery, development, clinical application	
Drug resistance		**Tumour biology**	
Gene and vector-based therapy		Angiogenesis, vasculogenesis, microcirculation	
Mechanisms of drug action		Migration and invasion	
New molecular targets		Tumour adhesion	
Pharmacology, pharmacogenetics and pharmacogenomics		Tumour metastasis and Cancer progression	
Preclinical radiotherapeutics		Tumour microenvironment	
Small molecule therapeutic agents			

Abstract (max 400 words)

☞

Executive summary

Application domain; indication and use	☞
Innovative component	☞
Objectives	☞
Target population	☞
Target profile	☞

Target product/device profile

Project description.	☞
Project category & unmet medical needs: addition indication for an existing "product" or a new product?	☞
Strategic fit and values, how well does this product fit with the core expertise and capabilities of the team.	☞
Value of the product to patient, offer therapeutic, safety or ease of use, advantages over existing or upcoming product.	☞
Competitive position: does the product have a competitive advantage?	☞
IP position.	☞
Rationale for success: why the team believes in the success of the product.	☞
Success factors: statement that would drive to a successful outcome.	☞
Key risk factors: statement identifying key risks.	☞
Consequence of stopping the project, what would happen?	☞
Possible alternative to the project.	☞

COORDINATOR AND PARTNERS

Project coordinator and partners

Name	*Know-how, knowledge, competences, skill (ie: management, collaborations, industrial and/or technology transfer…)*

Partner's details → one table for each partner

Title; Name			
Position			
Address			
E-mail		*Phone / Mobile*	

Publications and awards of the coordinator and his partners

Main publications of associated partners scientific and technical relevant to the project (max 5 for each one)

☞

Current and pending research awards held by the team; for each of them indicate leader, title, duration, level of support, funding body and type.

☞

INTELLECTUAL PROPERTY

Patent → one table for each patent filed or upcoming

Patent title	
Field of application	
Inventors	
Patent co-owners (institutions)	
Date of Invention disclosure	
Date of patent filing	
PCT number	
Awarded countries	
TTO management	
Potential agreement limiting use of IP?	

Expected potential intellectual property by the end of the project

☞

Existing partnerships (or in progess) → involved parties and partnership

☞

Key competiting intellectual property

Publication reference or PCT: list and indicate status of any competing IP (http://worldwide.espacenet.com/?locale=en_EP)

☞

How does it impact on the development of your modality?

☞

RESEARCH & DEVELOPMENT PLAN

A work plan is a planning and management tool which provides a framework for planning the work and is a guide during the period for carrying out that work. It is a scientific roadmap with an increased clarity. When it is approved, he serves as a guide to actions to be taken in order to reach the objective. It is written so as to be transparent to anyone and justifying the actions to be taken. Describe the scientific project and the work plan: scientific hypothesis, rationale, milestones, Go/No-Go criteria, task, methodology, design, deliverable, regulatory constraints, Gantt chart, timelines, expectations in terms of technology transfer… A milestone is a scheduled and important checkpoint that marks the completion of a work package, a major deliverable or a set of deliverables have been completed after successfully conducting the planned work (tasks). Milestones are used to validate the project progression and make Go/No-Go decisions based on progress measured against objectives and on project value. Deliverables are reviewed at each milestone to validate if Go/No-Go criteria are met and to decide whether to further proceed with the project. It is essential to formulate as precisely as possible milestones, deliverables, Go/No-Go criteria.

Research & development plan

I. Scientific background: relevant results, mechanism of action, proof of concept in animal models, clinical/epidemiological data.
II. Innovative component: clinical indication, critical unmet need, economic/social impact, benefit of the targeted health issue.
III. Objectives.
IV. Research status: e.g. credentialing; supporting tools; modality creation; preclinical development, in vivo/in vitro.
V. Scientific description & work plan.
VI. Supporting references.

Milestones and decision making process → one table for each Work package.

	Main objective	Timeline
Workpackage 1 (WP1)	*title*	
Task 1		Y; M
Task 2		
…		
Deliverable 1		
Identified risks of the WP 1		
Go/No-Go criteria		
Decision if Go criteria is met		
Decision if Go criteria is not met		

Gantt chart → specifies tasks, deliverables and timelines.

	Deliverable	Year 1				Year 2				Year 3			
		1	2	3	4	1	2	3	4	1	2	3	4
WP 1 _ Task 1													
WP 1 _ Task 2													
…													

Simplified budget.

	Duration	Staff costs	Running costs	Equipment costs	Subcontracting	Total
WP1						
WP…						
Total						

MATWIN provides a high added-value pedagogical support but no funding, however to appreciate the needs, list the sources of funding.

Funding source	K€	Date	obtained -expected

PROJECT MANAGEMENT AND FEASIBILITY

Describe decision points by which scientific discoveries will be transformed into clinical modalities:

Management process and coordination between partners (meetings, progress tracking, regular reporting

☞

Decision-making process to track project progress.

☞

Project feasibility.

☞

COMMERCIAL POTENTIAL AND COMPETITIVE LANDSCAPE

Targeted market

As far as it is in the public domain, indicate the current and forecasted size of the worldwide market. Provide an indication to assess commercial potential of your modality (price of products/devices; your project will compete with; number of patients…).

☞

Competitive landscape → which of the following options would best describe your proposed work?

☞ *Fulfils a currently unmet need* ☐	☞ *Competes with current alternatives* ☐	☞ *Improves on current alternatives* ☐

Products/devices already on the market that your modality will compete with or replace

As far as it is in the public domain, describe the products/devices currently on the market and used by healthcare professions that your modality would compete with or replace. For each one, indicate the name(s) of the company marketing it.

☞

Competing academic/industrial groups and research & development stage of their projects

As far as it is in the public domain, list academic and industrial groups who are conducting research on projects that could competing with your modality once in the market. For each one, specify the topic and stage of their research, the expected launch date of their project compared with your modality and the competitive advantage of your modality.

☞

SWOT analysis

Strengths	**W**eaknesses
☞	☞
Opportunities	**T**hreats
☞	☞

UNDERTAKING

Head(s) of Departement

I confirm that I have read and that I support this application. I am not aware of any relevant information that has been withheld or of any information given that is misleading. I agree to the research carried out in my department. All necessary licences and approvals have been obtained or are being sought

Name and Department	Date and Signature
☞	

Host institution

I confirm that this application is submitted with the agreement of the host institution. The host institution is not aware of any relevant information that has been withheld or of any information given in the application that is misleading. I confirm that I have read and the host institution accepts the terms and conditions and any supplementary terms and conditions published with and/or referred to in the application form. The host institution understands that the terms and conditions may change during the process and it would then be required to sign its agreement to the new terms & conditions.

Name and Institution	Date and Signature
☞	

TTO, Patent Office

I confirm that this application is submitted with the agreement of the TTO

Name and institution	Date and Signature
☞	

Collaborator's)

I enclose a project application form for approval, completed in accordance with the guidelines. I am not aware of any relevant information that has been withheld or of any information given that is misleading. I have read the relevant undertakings, the supplementary terms and conditions published with and/or referred to in the application form and, if this application is successful, I agree to abide by them. I understand that the terms and conditions may change during the process and I would then be required to sign my agreement to the new terms & conditions.

Name and position	Date and Signature
☞	

Project Leader

I, undersigned confirm that I have (i) completed all sections and that all information given in this form is complete and true, (ii) obtained the agreement of collaborators and institutional contacts for their participation, (iii) gathered signatures of any named collaborators and institutional contacts. I agree that if the application be successful, some completed fields could be used for publication on the MATWIN website. I authorise the MATWIN society to share my application form for assessment, under confidentiality agreement condition for each person who accesses this.

Name	Date and Signature
☞	